FDA Committee Recommends Epinephrine Nasal Spray for Severe Allergic Reactions

The nasal spray is the first alternative to auto-injector needles

The U.S. Food and Drug Administration in White Oak, Md., on July 20, 2020. Sarah Silbiger/Getty Images

The Food and Drug Administration’s Pulmonary-Allergy Drugs Advisory Committee voted on May 11 to recommend an epinephrine nasal spray product for the treatment of severe allergic reactions, including anaphylaxis.

The 22-member advisory committee voted 16–6 to recommend approval of the 2 milligram epinephrine saline-based spray, marketed as Neffy, for adults.